Cargando…

New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a)

Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). There are abundant and unequivocal data to indicate that low-density lipoproteins (LDL) are a cause of ASCVD. Reduction of plasma low-density lipoprotein cholesterol (LDL-C) by medical therapy such as statin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Kyung An, Park, Hun-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Lipidology and Atherosclerosis 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9884549/ https://www.ncbi.nlm.nih.gov/pubmed/36761062 http://dx.doi.org/10.12997/jla.2023.12.1.37

Ejemplares similares

New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
por: Kim, Ji Yoon, et al.
Publicado: (2023)

When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson
por: Huygen, Lisa P.M., et al.
Publicado: (2022)

Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia
por: Zheng, Dongdan, et al.
Publicado: (2017)

Bempedoic Acid: The New Kid on the Block for the Treatment of Dyslipidemia and LDL Cholesterol: A Narrative Review
por: Alam, Uazman, et al.
Publicado: (2021)

LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
por: Kayikcioglu, Meral
Publicado: (2021)

Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes
por: Sánchez-Quesada, Jose Luis, et al.
Publicado: (2013)

ALERT-LDL: adherence to guidelines in the treatment of patients with dyslipidemia
por: Bosso, Giorgio, et al.
Publicado: (2021)

Endothelial Function in Dyslipidemia: Roles of LDL-Cholesterol, HDL-Cholesterol and Triglycerides
por: Higashi, Yukihito
Publicado: (2023)

Hypertension and Dyslipidemia Combined Therapeutic Approaches
por: Borghi, Claudio, et al.
Publicado: (2022)

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
por: Deshmukh, Harshal A., et al.
Publicado: (2012)

Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments
por: Yang, Ye Seul, et al.
Publicado: (2020)

Baseline LDL-C and Lp(a) Elevations Portend a High Risk of Coronary Revascularization in Patients after Stent Placement
por: Cai, Anping, et al.
Publicado: (2013)

Effect of physician characteristics and knowledge on the quality of dyslipidemia management and LDL–C target goal achievement in China: Subgroup analysis of the Dyslipidemia International Study
por: Ding, Rongjing, et al.
Publicado: (2017)

Dyslipidemia-Induced Neuropathy in Mice: The Role of oxLDL/LOX-1
por: Vincent, Andrea M., et al.
Publicado: (2009)

Reducing saturated fat intake lowers LDL-C but increases Lp(a) levels in African Americans: the GET-READI feeding trial
por: Law, Hayley G., et al.
Publicado: (2023)

New classes of Lp-spaces
por: Bourgain, Jean
Publicado: (1981)

Treatment of dyslipidemia in the elderly
por: Shao, Hong, et al.
Publicado: (2011)

LP1 and LP2: Dual-Target MOPr/DOPr Ligands as Drug Candidates for Persistent Pain Relief
por: Pasquinucci, Lorella, et al.
Publicado: (2021)

Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus
por: Kostner, Karam M., et al.
Publicado: (2022)

Lp-PLA2 Inhibition—The Atherosclerosis Panacea?
por: Karakas, Mahir, et al.
Publicado: (2010)

Apolipoprotein E4 Exaggerates Diabetic Dyslipidemia and Atherosclerosis in Mice Lacking the LDL Receptor
por: Johnson, Lance A., et al.
Publicado: (2011)

Cholesterol: The Good, the Bad, and the Ugly – Therapeutic Targets for the Treatment of Dyslipidemia
por: Elshourbagy, Nabil A., et al.
Publicado: (2014)

A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
por: Kim, Kyuho, et al.
Publicado: (2022)

Dyslipidemia in rat fed with high-fat diet is not associated with PCSK9-LDL-receptor pathway but ageing
por: Jia, Yan-Jun, et al.
Publicado: (2013)

Atherogenic Dyslipidemias: Unmet Needs and the Therapeutic Potential of Emerging and Novel Approaches and Drugs
por: Romandini, Alessandra, et al.
Publicado: (2023)

A Modern Approach to Dyslipidemia
por: Berberich, Amanda J, et al.
Publicado: (2021)

Genetic invalidation of Lp-PLA(2) as a therapeutic target: Large-scale study of five functional Lp-PLA(2)-lowering alleles
por: Gregson, John M, et al.
Publicado: (2016)

Treatment of dyslipidemia
por: Tonkin, Andrew, et al.
Publicado: (2014)

Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?
por: Enkhmaa, Byambaa, et al.
Publicado: (2020)

Lp-PLA(2) Inhibitors for the Reduction of Cardiovascular Events
por: Steen, Dylan L., et al.
Publicado: (2013)

Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia
por: Alwhaibi, Monira, et al.
Publicado: (2019)

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia
por: Kastelein, John J.P., et al.
Publicado: (2017)

Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential
por: Deng, Chang-Feng, et al.
Publicado: (2022)

Advances in Treatment of Dyslipidemia
por: Dybiec, Jill, et al.
Publicado: (2023)

Novel therapeutic targets and agents for pediatric dyslipidemia
por: Sunil, Bhuvana, et al.
Publicado: (2021)

Lp(a): a New Pathway to Target?
por: Nurmohamed, Nick S., et al.
Publicado: (2022)

Treatment of dyslipidemia in patients with type 2 diabetes
por: Vijayaraghavan, Krishnaswami
Publicado: (2010)

Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital
por: Sangsawang, Tamon, et al.
Publicado: (2015)

Lp(a): When and how to measure it
por: Cegla, Jaimini, et al.
Publicado: (2020)

Hydrogen sulfide improves ox-LDL-induced expression levels of Lp-PLA(2) in THP-1 monocytes via the p38MAPK pathway
por: Hu, Heng-Jing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cqfg4n33dnpsff3a9nvm7n5g73